Accéder au contenu
Merck

Measurement of Cyclic AMP and Cyclic GMP in Xenopus Oocytes Stimulated with Angiotensin II and Atrial Natriuretic Factor.

Methods in molecular medicine (2001-01-01)
H Ji
RÉSUMÉ

Angiotensin type-1 receptors (AT(1) receptors) mediate various physiological actions of angiotensin (Ang II) via multiple-signal transduction pathways (1). In addition to the phospholipase C pathway and dihydropyridine-sensitive voltage-dependent calcium channels, AT(1) receptors can couple to inhibition of adenylate cyclase via the guanine nucleotide binding protein Gi. Beside acting directly through G(i), AT(1) receptors can modulate levels of cyclic AMP (cAMP) indirectly through receptor crosstalk. cAMP is a major second messenger of many G protein coupled receptors. One group of receptors (e.g., (3-adreno-receptors, A(2) adenosine, D(1) dopamine, H(2) histamine, and some prostanoid receptors) elevate cAMP by activating adenylate cyclase through G(s), whereas a second group (a(2) adrenoreceptors, A1 adenosine, D(2) dopamine, 5HT(1) metabotropic glutamate, and i opioid receptors) reduce cAMP levels by inhibiting adenylate cyclase via G(i). Accumulating evidence indicates that signaling crosstalk can occur between AT receptors and receptors for atrial natriuretic factor (ANF) (2), bradykinin (3), catecholamines (4), adrenocorticotropin releasing hormone (5), vasopressin (6), and dopamine (7). Ang II is also found to indirectly modulate cyclic GMP (cGMP) levels via nitric oxide (8,9).

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
3-Isobutyl-1-methylxanthine, A cell-permeable, non-specific inhibitor of cAMP and cGMP phosphodiesterases (IC₅₀ = 2-50 µM).
Sigma-Aldrich
Rolipram, A cell-permeable, selective inhibitor of cAMP-specific phosphodiesterase (PDE IV; IC₅₀ = 800 nM).